First in-human, intracisternal dosing of RGX-111, an investigational AAV gene therapy, for a 21-month-old child with mucopolysaccharidosis type I (MPS I): 3.5 year follow-upRaymond Wang, Laura Rosa Pisani, Shih‐hsin Kan et al.|Molecular Genetics and Metabolism|2024Cited by 1